Search results
Results From The WOW.Com Content Network
Biotech Consortium India Limited (BCIL), New Delhi was incorporated as public limited company in 1990 under The Companies Act, 1956. [1] The consortium is promoted by the Department of Biotechnology , Government of India and financed by the All India Financial Institutions and some corporate sectors. [ 2 ]
This page was last edited on 18 September 2020, at 16:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The first Indian biotechnology company to be established was Biocon, which was founded by Kiran Mazumdar-Shaw in 1978. [3] The Indian biotechnology industry formally began in 1986 with the establishment of the Department of Biotechnology (DBT) by the Ministry of Science and Technology. [4]
In December 2015, the Department of Biotechnology launched the National Biotechnology Development Strategy 2015–2020 programme. The stated aim of the programme is to intensify research in the fields of vaccines, humane genome, infectious and chronic diseases, crop science, animal agriculture and aquaculture, food and nutrition, environmental management and technologies for clean energy.
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India.It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
The New Delhi-based Federation of Indian Publishers told Reuters it had filed a case at the Delhi High Court, which is already hearing a similar lawsuit against OpenAI.
Panacea Biotec has a focused presence in nephrology therapy in the highly specialized organ transplantation and dialysis management segments. It offers a range of pre-transplant and post-transplant therapies that include drugs such as lanthanum carbonate, sevelamer, and valganciclovir in conventional and novel drug delivery systems.